Itopride hydrochloride

Phase 3Small molecule

FForest Laboratories

Itopride hydrochloride is one of 34 small molecule programs targeting Dyspepsia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DyspepsiaActive, not recruiting

DyspepsiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

99 competitors in Dyspepsia

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Phase 3

2 2

Tofranil

Sanofi

Phase 3

1 3

Elavil

AstraZeneca

Phase 3

1 4

Pamelor

SSpecgx

Phase 3

1 5

Neurontin

VViatris Specialty LLC

Phase 3

1 6

Domperidone

Johnson & Johnson

Phase 3

3 7

Xifaxan

SSalix

Phase 2

3 8

Nereus

VVanda Pharmaceuticals

Phase 2

1 9

Aciphex

Akero Therapeutics

Phase 2

1 10

GW679769

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dyspepsia4 trials

Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Completed·FForest Laboratories·Phase 3·NCT00112190·645 enrolled

Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Completed·FForest Laboratories·Phase 3·NCT00112177·500 enrolled

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Active, not recruiting·AAbbott·Phase 3·NCT06217393·564 enrolled

Show 1 more trial

Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia

Completed·FForest Laboratories·Phase 3·NCT00110968·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Itopride hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Itopride hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Itopride hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Forest Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FForest Laboratories

Itopride hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dyspepsia4 trials

References

Drug Info

Quick Facts

Related News